[go: up one dir, main page]

WO2013009165A1 - Peptide pouvant se lier à une molécule d'antigène des leucocytes humains (hla), vaccin contre le cancer dérivé dudit peptide et utilisation dudit vaccin contre le cancer - Google Patents

Peptide pouvant se lier à une molécule d'antigène des leucocytes humains (hla), vaccin contre le cancer dérivé dudit peptide et utilisation dudit vaccin contre le cancer Download PDF

Info

Publication number
WO2013009165A1
WO2013009165A1 PCT/MY2012/000198 MY2012000198W WO2013009165A1 WO 2013009165 A1 WO2013009165 A1 WO 2013009165A1 MY 2012000198 W MY2012000198 W MY 2012000198W WO 2013009165 A1 WO2013009165 A1 WO 2013009165A1
Authority
WO
WIPO (PCT)
Prior art keywords
mage
peptide
cancer
cells
cancer vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/MY2012/000198
Other languages
English (en)
Inventor
Sok Ching Cheong
Soo Hwang Teo
Kue Peng LIM
Rosnah Mohd Zain
Zainal Ariff ABDUL RAHMAN
Sathibalan Ponniah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Initiatives Foundation
Original Assignee
Cancer Research Initiatives Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Initiatives Foundation filed Critical Cancer Research Initiatives Foundation
Publication of WO2013009165A1 publication Critical patent/WO2013009165A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to immunogenecity and peptide chemistry.
  • Cancer is one of the life-threatening diseases and a major health problem worldwide. Ongoing intensive research has been done to determine the origin and cause of cancer, and to understand the transformation of normal cells into cancerous cells. Unfortunately, the resolution to these issues has not been completely uncovered.
  • Oral cancer is a debilitating disease that is the 8th and 13th most common malignancy worldwide for males and females respectively, as stated in Gene Expression in Human Oral Squamous Cell Carcinoma is Influenced by Risk Factor Exposure (Cheong et a/., 2009). Although the epidemiology of oral cancer is well-established, the prognosis and survival rates for oral cancer patients have not improved significantly over the past three decades.
  • Immunotherapy has been a big research area since it is known to people skilled in the art that the immune system plays an important role in the elimination of tumour cells.
  • the outcomes are not always positive. Nevertheless, these outcomes have led and directed the production of many different types of treatments.
  • One of the treatments based mainly on immunotherapy is the use of therapeutic monoclonal antibodies, for example, cetuximab, panitumumab, and matuzumab. Their capabilities in modulating the immune system allow them to be considered as one of the more successful immunotherapies. Based on this, the therapeutic monoclonal antibody has been used in the treatment of head and neck cancers.
  • patent documents can be found describing the use of immunotherapy in treating different types of cancers. These patent documents may have disclosed the method of treating, inhibiting or preventing the recurrence of cancer that involve the concept of immunotherapy, but the work that has been done in most of the patent documents are expressed specifically on a particular cancer. Therefore, the disclosed methods may not necessarily work in treating or inhibiting oral cancer, or preventing the recurrence of oral cancer.
  • some of the methods being used as a single modality treatment or in combination for the treatment of oral cancer include surgery, radiotherapy and chemotherapy.
  • surgery is associated with high morbidity in particular, because the mouth is a vital organ, and surgical intervention will severely affect the quality of life. Further, extensive surgery to ensure that the surgical margins are clear is sometimes not possible as the mouth is located close to critical blood vessels and anatomical structures.
  • typical oral cancer patients are those over 60 years of age and often have co-morbidity factors and may not be amenable to surgery.
  • the use of radiotherapies and chemotherapies are far more limited than surgery due to the radiation toxicity in normal cells that lay close to the target tumor volume. Further, the radiotherapy and chemotherapy treatments cause side effects, which the nature, severity, and longevity of the side effects depends on the organs that receive the radiation, the type of radiation, dose, fractionation and concurrent chemotherapy, and the patient.
  • an alternative treatment strategy is crucial to prolong the life of the oral cancer patients. Therefore, it is an aim of this present invention to address the aforesaid technical disadvantages by introducing a peptide, a cancer vaccine derived from said peptide and a use of the cancer vaccine, which is capable of inducing the immune system of a subject to recognize oral cancer cells as being foreign wherein said subject is an oral cancer patient.
  • the present invention relates to a peptide comprising at least an amino acid sequence selected from at least a portion of Melanoma antigen family D4b (MAGE-D4b) protein, wherein said peptide being capable of binding with at least a human leukocyte antigen (HLA) molecule.
  • the amino acid sequence mentioned herein is selected from any one or a combination of SEQ ID NO. 1 to SEQ ID NO. 12 of said MAGE-D4b protein as listed in Table 1.
  • the structure of the peptide sequences may be modified or changed, and the modification or change herein includes, but not limited to substitution, deletion or insertion. For substitution, at least one amino acid in said peptide is being substituted by another amino acid.
  • said peptide For deletion, at least one amino acid in said peptide is being deleted.
  • said peptide is being inserted with at least one amino acid.
  • the additional amino acid is inserted at the C-terminus or the N- terminus.
  • HLA human leukocyte antigen
  • said peptide Upon binding with the human leukocyte antigen (HLA) molecule, said peptide is capable of inducing the immune system of a subject to recognize oral cancer cells as being foreign.
  • HLA human leukocyte antigen
  • the subject herein refers to an oral cancer patient.
  • the peptide as set forth in the present invention, is used to produce a cancer vaccine, wherein said cancer vaccine is capable of inducing the immune system of the subject to recognize oral cancer cells as being foreign.
  • a cancer vaccine comprising at least one peptide as claimed in the present invention. Due to the unique binding specificity between a human leukocyte antigen (HLA) and a peptide, the cancer vaccine is developed specifically using the peptide of the present invention, and the cancer vaccine is formulated for a subject whose antigen is able to bind to any one or a combination of human leukocyte antigen A2 (HLA-A2), human leukocyte antigen A1 1 (HLA-A1 1 ) and human leukocyte antigen A24 (HLA- A24). Moreover, the cancer vaccine further comprises an adjuvant that enhances the effectiveness of the cancer vaccine.
  • HLA human leukocyte antigen
  • HLA-A24 human leukocyte antigen A24
  • the adjuvant preferably used herein is an immunomodulatory cytokine
  • the immunomodulatory cytokine preferably used herein is a granulocyte-macrophage colony- stimulating factor (GM-CSF).
  • GM-CSF granulocyte-macrophage colony- stimulating factor
  • the use of the cancer vaccine is also disclosed in the present invention, which the use of the cancer vaccine is capable of inducing the immune system of the subject to recognize oral cancer cells as being foreign. It is an object of the present invention to provide a peptide that comprises at least an amino acid sequence selected from any one or a combination of SEQ ID NO. 1 to SEQ ID NO. 12 of said MAGE-D4b protein as listed in Table 1 .
  • HLA human leukocyte antigen
  • HLA human leukocyte antigen
  • HLA human leukocyte antigen
  • Figure 1 illustrates the qPCR data, showing the over-expression of MAGE- D4b mRNA level that is significantly higher in oral squamous cell carcinoma (OSCC) as compared to normal tissues.
  • OSCC oral squamous cell carcinoma
  • Figure 2 illustrates the expression of AGE-D4b in human tissues cDNA panel: 1) liver; 2) skeletal muscle; 3) kidney; 4) pancreas; 5) spleen; 6) thymus; 7) prostate; 8) testis; 9) ovary; 10) small intestine; 11) colon; 12) peripheral leukocytes; 13) 204T oral cancer cell line; 14) A549 lung cancer cell line.
  • Figure 3 illustrates the binding ability of different peptides towards major histocompatibility complex ( HC) A2 molecules.
  • HC major histocompatibility complex
  • Figure 4 illustrates the dimer assay of the affinity of different peptides in attracting and binding with the CD8 + cytotoxic T cells.
  • Figure 5 illustrates the enzyme-linked immunosorbent spot (ELISPOT) assay: (a) The cytotoxic activities of the CD8 + cytotoxic T cells in secreting granzyme when exposed to the MAGE-D4b-HLA complex, (b) The cytotoxic activities of the CD8 + cytotoxic T cells in secreting IFN-g when exposed to the MAGE- D4b-HLA complex.
  • ELISPOT enzyme-linked immunosorbent spot
  • Figure 6 illustrates the over-expression of MAGE-D4b in oral squamous cell carcinoma (OSCC): (a) The distribution of the intensity of immunohistochemistry (IHC) staining in oral squamous cell carcinoma (OSCC) and normal oral mucosa that demonstrates the high levels of MAGE- D4b in oral squamous cell carcinoma (OSCC) and low levels of MAGE-D4b in normal oral mucosa, (b) The immunohistochemistry (IHC) staining of oral squamous cell carcinomas (OSCC) (I, II, III) that demonstrates the 3+ (I), 2+ (II), 1 + (III) intensity or lack of expression in normal oral mucosa (IV).
  • OSCC oral squamous cell carcinoma
  • Figure 8 illustrates the over-expression of MAGE-D4b in promoting evasion of apoptosis.
  • Figure 9 illustrates the over-expression of MAGE-D4b in promoting cell migration but not invasion: (a) Wound closure images of ORL-48/MAGE-D4b and ORL-150/ AGE-D4b, and their respective control at 0 and 20 hour after the mitomycin C treatment, and a histogram indicating an increased of wound closure in ORL-48/MAGE-D4b and ORL-150/MAGE-D4b in comparison to their respective vector controls, (b) Wound closure images of ORL-48/MAGE- D4b and ORL-150/MAGE-D4b, and their respective control with and without MAGE-D4b siRNA knock-down, and a histogram showing reduced wound closure in cells with MAGE-D4b knocked-down.
  • MHC major histocompatibility complex
  • APC professional antigen presenting cells
  • the complexes formed between the major histocompatibility complex (MHC) Class I molecules and peptides are recognized by the CD8 + cytotoxic T cells and subsequently triggers a response from the CD8 + cytotoxic T cells.
  • MHC major histocompatibility complex
  • MHC major histocompatibility complex
  • major histocompatibility complex (MHC) molecules are extremely polymorphic. The polymorphism of these major histocompatibility complex (MHC) molecules has consequently constituted challenges to T cell epitope discovery, since each of the major histocompatibility complex (MHC) molecules has unique binding specificity.
  • HLA human leukocyte antigen
  • MAGE-D4b Melanoma antigen family D4b
  • OSCC oral squamous cell carcinoma
  • FIG. 1 the quantitative real-time polymerase chain reaction data shows the range of MAGE-D4b expressions in oral squamous cell carcinoma (OSCC) tissues that is significantly higher as compared to normal tissues.
  • FIG 6(b) the immunohistochemistry pictures of MAGE-D4b staining are illustrated. Further analysis has been done in order to determine whether the MAGE-D4b can be potentially developed as therapeutic target with negligible vital-organ related toxicity.
  • the analysis employs polymerase chain reaction (PCR) on the complementary DNA (cDNA) panel of human tissues and the results of the analysis, as illustrated in Figure 2, have showed that MAGE-D4b was expressed at very low levels in majority of the normal tissues tested, except for ovary, thymus, and colon.
  • PCR polymerase chain reaction
  • the inventors of the present invention have further analysed the oral squamous cell carcinoma (OSCC) cell lines by treating the oral squamous cell carcinoma (OSCC) cell lines with the demethylating agent of 5 Aza-deoxycitidine.
  • OSCC oral squamous cell carcinoma
  • the inventors have observed re-expressions of MAGE-D4b in oral squamous cell carcinoma (OSCC) cell lines after being treated with the demethylating agent.
  • the observations clearly state that the expression of MAGE-D4b is due to loss of DNA methylation during tumour progression. As a result, the MAGE family proteins tend to be expressed in tumours rather than normal tissues.
  • the present invention discloses a peptide comprising at least an amino acid sequence selected from at least a portion of MAGE-D4b protein, wherein said peptide is capable of binding with at least a human leukocyte antigen (HLA) molecule. Also disclosed in the present invention is the binding of said peptide with the human leukocyte antigen (HLA) molecule that is capable of inducing the immune system of a subject to recognize oral cancer cells as being foreign.
  • HLA human leukocyte antigen
  • the binding between a human leukocyte antigen (HLA) and a peptide is distinctive.
  • HLA human leukocyte antigen
  • the subject mentioned herein can be any mammal but preferably a human. More preferably, the human is an oral cancer patient with tumours having the expression of MAGE-D4b.
  • the expression of MAGE-D4b may be determined by immunohistochemistry staining, quantitative polymerase chain reaction (PCR) or any other methods that could indicate whether the expression of MAGE-D4b is present and/or elevated in tumour tissue in comparison to normal tissues.
  • HLA-A2 human leukocyte antigen A2
  • HLA-A1 1 human leukocyte antigen A1 1
  • HLA-A24 human leukocyte antigen A24
  • HLA human leukocyte antigen
  • amino acid sequence mentioned herein is selected from any one or a combination of SEQ ID NO. 1 to SEQ ID NO. 12 of said MAGE-D4b protein, as tabulated in Table 1 below:
  • the peptides may be prepared synthetically or isolated naturally from natural sources, such as native tumours or pathogenic organisms. Synthetic preparations may include recombinant DNA technology or chemical synthesis.
  • modifications and changes may be made to the structure of these peptide sequences, which the modifications or changes mentioned herein refers to the change or modification of at least one amino acid in these peptide sequences.
  • the change of amino acids include, but not limited to substitution, deletion or insertion.
  • substitution at least one of the amino acid in any one of the peptide sequences in Table 1 may be replaced by another amino acid with similar chemical properties.
  • insertion at least one additional amino acid may be inserted in any part of the peptide sequence selected from Table 1. More preferably, the additional amino acid is inserted at the N-terminus or the C-terminus of the peptide sequence.
  • any one of the amino acid in a peptide sequence selected from Table 1 may be removed.
  • the amino acid is selected in a way that it will not deteriorate the immuno properties of the peptide, which the immuno properties of the peptide include the binding affinity between the human leukocyte antigen (HLA) molecule and the peptide, and the capability of inducing the immune system of the subject to recognize oral cancer cells as being foreign.
  • the modified or changed peptide sequence may enhance the properties of the peptides, for instant, the peptide stability in an expression system or the stability of protein-protein binding such as HLA- peptide binding.
  • Table 2 below is used as a reference to the peptide sequences tabulated in Table 1.
  • the peptides may be used to manufacture a cancer vaccine, which the cancer vaccine is capable of inducing the immune system of the subject to recognize oral cancer cells.
  • the peptide in the cancer vaccine comprises at least an amino acid sequence selected from at least a portion of MAGE-D4b protein wherein said amino acid sequence is selected from any one or a combination of SEQ ID NO. 1 to SEQ ID NO. 12 tabulated in Table 1.
  • the cancer vaccine may be preventative or therapeutic.
  • the cancer vaccine is developed specifically using the peptide of the present invention, so that the peptide can bind to the human leukocyte antigen (HLA) molecule successfully and subsequently triggers a response from the CD8 + cytotoxic T cells to eradicate oral cancer cells. Based on this reason, said cancer vaccine is formulated according to the type of antigen possessed by a particular subject. If the subject possesses any one or a combination of the human leukocyte antigens (HLA) A2, A1 1 or A24, said cancer vaccine may be formulated based on the amino acid sequences of SEQ ID NO. 1 to SEQ ID NO. 12, as listed in Table 1.
  • the cancer vaccine may be formulated based on the amino acid sequences of SEQ ID NO. 10 to SEQ ID NO. 12 as listed in Table 1.
  • the amino acids in the SEQ ID NO. 1 to SEQ ID NO. 12 can be changed or modified by non-limiting examples of substitution, insertion and deletion. Therefore, numerous cancer vaccine can be produced from these modified peptide sequences. It is believed that the changes or modifications made herein do not depreciate the immuno properties of the cancer vaccine in a way that these cancer vaccines may produce the equivalent or increased T cell stimulatory properties.
  • the cancer vaccine of the present invention is developed based on the manner of administration of the cancer vaccine into the subject, which the manners of application includes non-limiting examples of oral application on a solid physiologically acceptable base or a physiologically acceptable dispersion, parenteral application, aerosol application, or the like.
  • parenteral application is injection, which includes intradermal, intravenous, intramuscular, intracutaneous, subcutaneous, intrathecal, intraduodenal, intraperitoneally and the like.
  • excipient is normally employed, which the excipient employed herein is pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like.
  • these oral formulations take the form solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
  • the cancer vaccine is preferably supplied in finely divided form along with a surfactant and a propellant, which the surfactant must be nontoxic, and preferably soluble in such propellant.
  • Non-limiting examples of the surfactant are the esters or partial esters of fatty acids containing from 6 to 22 carbon atoms such as caproic, octanoic, lauric, palmitic, stearic, linoleic, linolenic, olesteric, and oleic acids with an aliphatic polyhydric alcohol or its cyclic anhydride.
  • Mixed esters such as mixed or natural glycerides may also be employed.
  • the cancer vaccine of the present invention is preferably administered to the subject via injection.
  • the cancer vaccine may be formulated as freeze-dried or liquid preparations according to any means suitable in the art.
  • the freeze-drying of the cancer vaccine may enhance the shelf life and may ease storage as freeze-drying removes the water and seals the cancer vaccine in a vial.
  • the cancer vaccine Prior to the administration, the cancer vaccine is reconstituted into its original form ready to be injected to the subject.
  • Liquid form preparations include but are not limited to solutions, suspension, syrups, slurries, and emulsions.
  • the cancer vaccine may also be mixed with suitable liquid carrier or excipients that are pharmaceutically acceptable and compatible to the active ingredients in the cancer vaccine.
  • the suitable liquid carrier or excipient may be organic or inorganic solvents.
  • the examples of the inorganic solvents may include water, alcohol, saline solution, buffered saline solution, physiological saline solution, dextrose solution, water propylene glycol solutions, and the like, preferably in sterile form.
  • the cancer vaccine of the present invention is formulated as liquid solution.
  • the cancer vaccine may also be formulated in neutral or salt forms.
  • the pharmaceutically acceptable salts include acid addition salts formed with inorganic or organic acids.
  • the examples of the inorganic acids used herein may comprise hydrochloric acids, phosphoric acids and the like.
  • the examples of the organic acids used herein may comprise acetic, oxalic, tartaric, mandelic acids and the like.
  • Salts formed with the free carboxyl groups may also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides.
  • the salts formed with the free carboxyl groups may also be derived from organic bases such as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine, and the like.
  • the cancer vaccine may be produced in sustained release formulation or depot preparation.
  • Such formulation may be a capsule, sponge or gel that is composed of polysaccharides, for example.
  • Such formulation can be prepared using any means suitable in the art.
  • the cancer vaccine may be administered into a subject via inoculation, implantation, oral or rectal application. The implantation in this regard may be subcutaneously, intramuscularly or particularly at a desired target site.
  • Such cancer vaccine formulation, comprising the peptide of the present invention may be dispersed in a carrier matrix and/or contained within a reservoir surrounded by a rate-controlling membrane, which upon administration, effects a slow release of the cancer vaccine in the subject.
  • Carriers or membrane being used herein are preferably biocompatible or biodegradable.
  • Non-limiting examples of the carriers or membrane may include microparticles of poly(lactide-co-glycolide), polyacrylate, latex, starch, cellulose and dextran.
  • the cancer vaccine may be formulated to include a certain amount of auxiliary substances to enhance the effectiveness of the cancer vaccine, for instant, the immune response induced by the peptide may be enhanced, and/or the peptide may be stabilized.
  • the auxiliary substance may also reduce the frequency of administration necessary to generate a protective immune response.
  • the auxiliary substances may include any one of wetting or emulsifying agents, pH buffering agents, adjuvants or the like.
  • the auxiliary substance used in the present invention is an adjuvant.
  • Non-limiting examples of adjuvant are emulsifiers, muramyl dipeptides, pyridine, aqueous adjuvants such as aluminium hydroxide, chitosan-based adjuvants and any of the various saponins, oils and other substances known in the art.
  • the immunomodulatory cytokines is preferably used in the present invention.
  • Other non-limiting examples of immunomodulatory cytokine that may also be used include interferons, imiquimods, granulocyte-macrophage colony-stimulating factor (GM-CSF) and the like.
  • the immunomodulatory cytokine being used in the present invention is granulocyte-macrophage colony-stimulating factor (GM-CSF).
  • the cancer vaccine further comprising the adjuvant, as described herein, may be prepared using techniques that are known in the art, which includes, but not limited to mixing, sonication and microfluidation.
  • the cancer vaccine may be formulated based on a mixture or a combination of peptide sequences that has been disclosed in the present invention as tabulated in Table 1.
  • the peptide sequences may be changed or modified by non-limiting means of substitution, insertion or deletion. Therefore, numerous cancer vaccine may be formulated from these modified peptide sequences.
  • these peptide sequences may be used as a mix or in combination with the peptides disclosed in the present invention or other potential peptides that have already been discovered or to be discovered.
  • the potential peptides mentioned herein may relate to MAGE-D4b or other proteins.
  • the cancer vaccine is administered to a subject in a dosage formulation that is able to induce the immune system of the subject to recognize oral cancer cells as being foreign.
  • the effective quantity of the cancer vaccine to be administered into a subject depend on various factors, for instant, the capacity of the subject's immune system to synthesize antibodies, the route of administration and the degree of protection desired. Other physical factors of the subject include the species, breed, size, height, weight, age and overall health condition of the subject.
  • the cancer vaccine can be administered to a subject based on any schedule, provided that the administration of the cancer vaccine is capable of inducing the immune system of the subject to recognize oral cancer cells as being foreign, or sustaining protective immunity against oral cancer relapse.
  • the schedule of the administration together with the dosage formulation may be tailored according to the above-mentioned factors of the subject and also to meet the particular needs of the subject.
  • the precise amount of the cancer vaccine and the adjuvant to be administered, and the schedule of administration depend on the judgement of the practitioner.
  • one or more boosters may be followed upon the administration of the cancer vaccine to bolster and/or maintain the protective immunity.
  • the boosters may also be administered on an as-needed basis.
  • the dosage of the cancer vaccine to be administered may be lower at the beginning of the administration process and a higher dosage over the administration process.
  • the dosage of the cancer vaccine may be higher at the beginning of the administration process and a lower dosage over the administration process.
  • the administration schedule may include higher frequency of administration at the beginning of the administration process and a lower frequency of administration over the administration process to maintain the protective immunity.
  • the human leukocyte antigen (HLA) Class I molecules bound with the MAGE-D4b peptides are then presented to the CD8 + cytotoxic T cells which would subsequently be activated to recognize the MAGE-D4b peptides.
  • the activated CD8 + cells then survey the body and search for cells that have MAGE-D4b expressions. In this case, only oral cancer cells, which express MAGE-D4b, will have these peptides bound to the human leukocyte antigen (HLA) molecules on the cell surface. Hence, these cells will be targeted and destroyed by the CD8 + cytotoxic T cells.
  • human leukocyte antigen (HLA) Class II molecules bound with the MAGE-D4b peptides they would be presented to CD4 + cytotoxic T cells and these cells will be activated to secrete cytokines to further activate CD8 + cytotoxic T cells.
  • HLA human leukocyte antigen
  • Figure 3 has illustrated the binding affinity of seven different peptides derived from MAGE-D4b towards the human leukocyte antigen (HLA) molecules. It is clearly stated in Figure 3 that all of the seven peptides have higher binding affinity towards the human leukocyte antigen (HLA) molecules as compared to the negative control. These results therefore clarify that these peptides are able to bind with human leukocyte antigen (HLA) molecules.
  • the enzyme-linked immunosorbent spot (ELISPOT) assays have demonstrated the cytotoxic activities of the CD8 + cytotoxic T cells when exposed to MAGE-D4b over-expressing oral cancer cells.
  • the exposure of these MAGE-D4b over-expressing oral cancer cells to the CD8 + cytotoxic T cells has caused the CD8 + cytotoxic T cells to secrete granzyme and IFN-g.
  • the secretions of granzyme and IFN-g are indicated by horizontal lines in enzyme-linked immunosorbent spot (ELISPOT) assays in Figure 5(a) and Figure 5(b) respectively.
  • ELISPOT enzyme-linked immunosorbent spot
  • the 293FT cell line (Invitrogen, USA) used for the production of lentiviral stock was cultured in DMEM high glucose ⁇ Lonza, USA) supplemented with 10% FBS and 500 ⁇ 9/ ⁇ of Geneticin® (Invitrogen, USA).
  • Human foetal foreskin fibroblast 1 (HFFF1 ) used as feeder cells in organotypic co-cultures were cultured in DMEM supplemented with 10% FBS (Lonza, USA). This study was approved by the University Malaya ethical review board (Ethical Approval Code: DF OP 03/06/0018/(L)).
  • MAGE-D4b sense 5' CCAGAATCAGAACCGAGA 3' and antisense 5' CCAAAATCTCCGTCCTCA 3';
  • GAPDH sense 5' GAAGGTGAAGGTCGGAGTC 3' and
  • Ki67 sense 5' ACGAGACGCCTGGTTACTATC 3' and
  • CCNA1 sense 5' TGGATCAGAAAATGCCTTCC 3' and
  • CCNE1 sense 5' CTGGATGTTGACTGCCTTGAATT 3' and
  • CCNB1 sense 5' TCTG G ATAATG GTG AATG G ACA 3' and
  • MAGE-D4b The full length MAGE-D4b gene was amplified from pCMV6-SPORT6-MAGE- D4b expression clone ⁇ Invitrogen Life Technologies, USA; Cat # MGC: 74882) and cloned into plentiviral6.3/V5 expression construct vector (Invitrogen, USA) according to the manufacturer's instruction. MAGE-D4b was exogenously expressed in ORL-48, ORL-150 and ORL-195. For viral production, the MAGE-D4b lentiviral construct or vector alone was co-transfected with ViraPowerTM packaging mix using LipofectamineTM (Invitrogen, USA) into 293FT viral producing cell lines.
  • Viral supernatants were harvested 24 hours later and filtered using a 0.45 ⁇ syringe filter.
  • the ORL-48, ORL-150 and ORL-195 were transduced with the viral supernatant using 10 g/ml of polybrene (Sigma, USA).
  • Cells exogenously expressing MAGE-D4b and vector control cells were selected using 5 ⁇ g/ml of blasticidin (Invitrogen, USA).
  • the MAGE-D4b transduced cells will be referred to as ORL-48/MAGE-D4b, ORL- 150/MAGE-D4b or ORL-195/MAGE-D4b, and the cells that are transduced with the vector only are designated as ORL-48/pLenti, ORL-150/pLenti or ORL-195/pLenti herein.
  • Immunohistochemistry IHC
  • MAGE-D4b was examined by immunohistochemistry (IHC) using the Dakocytomation Envision* Dual Link System-HRP (DAB + ) kit (Dako, USA) on 40 oral squamous cell carcinoma (OSCC) and 1 1 normal oral mucosa tissues.
  • the demographic features of the oral squamous cell carcinoma (OSCC) patients included in the immunohistochemistry (IHC) analysis were summarized in Table 3 below.
  • RHO expression was determined in ORL-48/MAGE-D4b and ORL-48/pLenti xenografts.
  • Immunohistochemistry was performed using MAGE-D4b ⁇ 1:100: Sigma, USA), Pan Rho + RAC (1, 2) + CDC42 (1:300; Abeam, USA) based on the work done in Transcriptional Profiling of Oral Squamous Cell Carcinoma Using Formalin-fixed Paraffin- embedded Samples (Saleh et al., 2010).
  • the receiver operating characteristic (ROC) curve was used to identify the best cut-off points in scoring the expression of MAGE-D4b for specificity and sensitivity. Any discrepancies were discussed and a consensus agreement was reached to obtain a final definitive score.
  • ROC receiver operating characteristic
  • Total protein was extracted based on the work disclosed in Establishment and Characterization of Asian Oral Cancer Cell Lines as in vitro Models to Study a Disease Prevalent in Asia (Hamid et al, 2008). 50 ⁇ g/lane of crude protein extracts resolved by SDS-PAGE were transferred onto nitrocellulose membrane using the Bio-Rad mini gel electrophoresis apparatus for 1 hour in transfer buffer (25 mM Tris base, 192 mM glycine and 20% methanol, pH 8.3).
  • Nitrocellulose membranes were treated with blocking solution (5% skimmed milk/PBS) for 1 hour at room temperature and probed with primary antibody (MAGE-D4b (1:100, Santa Cruz, USA); Pan Rho + RAC (1, 2, 3) + CDC42 (1:300; Abeam, USA); ROCK1 (1:200; Abeam, USA)).
  • primary antibody MAGE-D4b (1:100, Santa Cruz, USA
  • Pan Rho + RAC (1, 2, 3) + CDC42 (1:300; Abeam, USA
  • ROCK1 (1:200; Abeam, USA
  • MAGE-D4b The expression of MAGE-D4b was detected by enhanced chemiluminescence method (Pierce, USA) and visualized using the ChemilmagerTM Imaging Systems (Alpha Innotech, USA). To normalize for loading, the blots were probed with anti-a-tubulin (1:1,000; Sigma, USA) monoclonal antibody for 1 hour at room temperature and processed as described above.
  • the MAGE-D4b or vector transduced cells were seeded at 5x10 4 in 60 mm tissue culture dishes, harvested and counted using CASY® cell counter (Innovatis, Germany) every 24 hours over a 9-day period. The doubling times of each of the cell lines were calculated by plotting the total cell number in log 2 scale against time. The data was averaged from three experiments. The effect of MAGE-D4b over-expression on tumour growth was also assessed in 4-week-old athymic Nude-Foxn1 nu ⁇ Harlan Laboratories, USA). Briefly, ORL-48/MAGE-D4b and ORL-48/pLenti cells were subcutaneously injected into the flank of the animal at a concentration of 2x10 6 cells.
  • mice Five mice were used for each cell line. In post-transplantation, the mice were examined every other day for tumour development. Tumour volume was determined based on the formula 1 /2 (length ⁇ width 2 ). After 6 weeks of observations, all animals were euthanized and tumours were excised for histology evaluation. The experiments were performed twice. All experimental procedures were carried out as in accordance with National Institute of Health's Institutional Animal Care and Use Committee regulations.
  • UV irradiation was used to induce apoptosis in this study.
  • the sensitivity of each cell line against UV was determined by exposing the cells to a variation of ultraviolet (UV) doses (0-100 J/m 2 ). After the ultraviolet (UV) irradiation, the cells were allowed to recover over a period of 16 hours. Subsequently, viable and dead cells were determined using CASY® cell counter.
  • the cells were irradiated and harvested for cell cycle analysis by staining for propidium iodide (PI; Sigma, USA) , apoptotic index by double staining with Annexin V-FITC (BD Bioscience, USA) and propidium iodide (PI), and the cells were analyzed using the flow cytometer (BD Biosciences, USA).
  • PI propidium iodide
  • PI apoptotic index by double staining with Annexin V-FITC
  • PI propidium iodide
  • the monolayer wound healing assay was carried out based on the work done in Cell Migration and Invasion Assays (Valster et al., 2005). Briefly, 4x10 5 cells were seeded in duplicate in 60 mm culture dish and grown over 16 hours. The cells were then treated with 10 ⁇ g/ml of mitomycin C for 2 hours and two parallel scratches were made on the monolayer using a yellow pipette tip. The wound areas were recorded under the microscope at the time point of 0th- hour and 20th-hour. The images of the open wound areas were then analyzed using the TScratch analysis software as described in A Novel and Simple Software Tool for Automated Analysis of Monolayer Wound Healing Assays (Geback er a/., 2009).
  • the invasion assay was performed based on the work done in Development of a Quantitative Method to Analyse Tumour Cell Invasion in Organotypic Culture (Nystrom et ai , 2005). Briefly, 1 ml gel mix (type I collagen, Matrigel, 10x DMEM, FBS [4:4: 1 : 1 ] containing 1 x10 6 fibroblasts) at pH7 was added to each 12-well insert placed in the recesses of 12-well culture plates. The gel mix was left to solidify for 30 minutes at 37°C and fibroblast culture medium (DMEM containing 10% (v/v) foetal bovine serum and 2mM L-glutamine) was added and the culture plates were incubated overnight at 37°C.
  • DMEM fibroblast culture medium
  • the agar-gel was dissected, embedded in paraffin, sectioned and stained with hematoxylin and eosin.
  • the invasion index was calculated using Image J software as described in Fibroblast-led Collective Invasion of Carcinoma Cells with Differing Roles for RhoGTPases in Leading and Following Cells (Gaggioli et al., 2007) with minor modifications.
  • MAGE-D4b was found to be over-expressed in the majority of oral squamous cell carcinoma (OSCC) tissues at both mRNA and at protein levels.
  • the immunohistochemistry (IHC) analysis demonstrated that 39 over 40 (97.5%) of the oral squamous cell carcinoma (OSCC) tissues had expression of MAGE-D4b protein (p ⁇ 0.001 ).
  • OSCC oral squamous cell carcinoma
  • MAGE-D4b was consistently over-expressed in a large percentage of oral squamous cell carcinoma (OSCC), we have therefore determined its role in cell proliferation. MAGE-D4b was exogenousiy expressed in two oral cancer cell lines (ORL-48 and ORL-150).
  • ORL-48/MAGE-D4b and ORL-195/MAGE-D4b were relatively resistant to cell killing in comparison to the vector control cells, as illustrated in Figure 8(a).
  • the monolayer wound healing assays is a simple and effective way to study the migration of tumour cells.
  • the ability of ORL-48/MAGE-D4b and ORL- 150/MAGE-D4b cells to migrate in comparison to their respective vector control cells were measured by the rate of wound closure.
  • MAGE-D4b was shown to increase cell proliferation rate and this could lead to wound closure, we treated the cells with mitomycin C before conducting the wound healing assays. Further, to ensure that the mitomycin C has effectively blocked cell proliferation for the duration of the migration assay, we determined the levels of cell cycle proteins at the Oth-hour and 20th-hour of the post mitomycin C treatment.
  • Rho/RAC/CDC42 proteins was shown to be up- regulated in the ORL-48/MAGE-D4b cells in comparison to ORL-48/pLenti cells, as illustrated in Figure 9(e). Furthermore, the immunohistochemistry (IHC) analysis of tumours formed in mice injected with the ORL-48/MAGE- D4b cells or vector control cells also demonstrated high expression of Rho/RAC/CDC42 proteins in the ORL-48/MAGE-D4b tumours where the expression was observed in both membrane and cytoplasm, as illustrated in Figure 9(f).
  • IHC immunohistochemistry
  • MAGE-D4b is a member of the Type II MAGE family and expected to be expressed more universally relative to Type I MAGE proteins, a growing body of evidence suggests that the expression of MAGE-D4b in normal tissues is limited, as stated in MAGE-E1, A New Member of the Melanoma-associated Antigen Gene Family and its Expression in Human Glioma (Sasaki et a/., 2001) and MAGE-D4B is a Novel Marker of Poor Prognosis and Potential Therapeutic Target Involved in Breast Cancer Tumourigenesis (Germano et a/., 201 1).
  • MAGE-E1 A New Member of the Melanoma- associated Antigen Gene Family and its Expression in Human Glioma
  • MAGE-D4B is a Novel Marker of Poor Prognosis and Potential Therapeutic Target Involved in Breast Cancer Tumourigenesis (Germano et a/., 2011)
  • Expression of MAGE-D4 A Novel MAGE Family Antigen, is Correlated with Tumor-cell Proliferation of Non-small Cell Lung Cancer (Ito ei al. , 2006) have shown that MAGE-D4b is over-expressed in several different cancers including glioma, breast and non-small cell lung cancer.
  • MAGE-D4b is a cancer-specific antigen and its limited expression in normal tissues further suggest that MAGE-D4b could be a good therapeutic target. Comparing with the clinico-pathological characteristics of our patients, we demonstrated that high expression of MAGE-D4b was significantly associated with lymph node metastasis and poor survival in oral squamous cell carcinoma (OSCC) patients suggesting that MAGE-D4b is an important gene in driving oral squamous cell carcinoma (OSCC) progression.
  • OSCC oral squamous cell carcinoma
  • MAGE-D4b was also found to be associated with tumour progression and poor disease outcome, as previously disclosed in the work done by Germano ei al., 201 1 thus indicating that the expression of MAGE-D4b has prognostic value, and its use as a prognostic marker should be explored further.
  • MAGE proteins have been investigated extensively for their use in immunotherapy. However, the development of effective therapeutic strategies often require an understanding of the role of the gene in driving carcinogenesis as many genetic abrogations in cancer could be merely "bystander" changes that may not necessarily contribute to cancer development.
  • MAGE proteins that have been reported to be over-expressed in head and neck cancers were from the MAGE-A family of proteins, as disclosed in Expression of Melanoma-associated Antigens in Oral Squamous Cell Carcinoma (Ries et al., 2008), Expression of MAGE-A M in Oral Squamous Cell Carcinoma (Mollaoglu et al., 2008), The Role of MAGE A2 in Head and Neck Cancer (Glazer et al., 201 1 ). From these, only one report demonstrated the role of MAGE-A2 in head and neck cancers, which the work in the report is done by Glazer ei a/., 201 1.
  • MAGE- D4b Information on the role of MAGE- D4b in cancer development is scarce with only one report on gene function in breast cancer, as illustrated in the work done by Germano ei a/., 201 1.
  • OSCC oral squamous cell carcinomas
  • MAGE-D4b For the first time in oral cancer, we demonstrated that over-expression of MAGE-D4b could increase cell growth both in vitro and in vivo. We further demonstrated that the increase in cell growth was not accompanied by a change in the expression of cell cycle proteins, which prompted us to determine if cell growth was due to a decrease in cell death. Interestingly, we demonstrated that MAGE-D4b over-expressing cells were less sensitive to UV-induced cell death and significantly less MAGE-D4b over-expressing cells undergo apoptosis compared to those transduced with the vector alone, suggesting that MAGE-D4b protects cells from undergoing apoptosis. Ki-67 is a marker of cell proliferation.
  • AGE-D4b expression has previously been associated with high Ki-67 labelling index, as previously disclosed in the works done by Ito ei a/., 2006 and Germano et a/., 201 1 , providing clues that MAGE-D4b could be involved in cell proliferation.
  • MAGE-D4b has a direct role in driving cell growth both in vitro and in vivo, and could do this by conferring a resistance to apoptosis. This is perhaps not too surprising as other MAGE family members including MAGE-A2 have been reported to play a role in increasing cell growth in head and neck cancer cell lines, as disclosed in the work done by Glazer et al., 201 1.
  • MAGE proteins have been shown to modulate apoptosis.
  • MAGE-A2 was shown to down-regulate the expression of BAX whilst MAGE-D1 has been shown to interact with XIAP, a member of the inhibitor of apoptosis (IAP) family, as disclosed in Neurotrophin Receptor- interacting MAGE Homologue is an Inducible Inhibitor of Apoptosis Protein- interacting Protein that Augments Cell Death (Jordan ei al., 2001).
  • IAP apoptosis
  • MAGE-A2 has been shown to bind with p53 and recruit the histone deacetylase 3 (HDAC) to down-regulate the transactivation function of p53, as disclosed in MAGE-A Tumor Antigens Target p53 Transactivation Function Through Histone Deacetylase Recruitment and Confer Resistance to Chemotherapeutic Agents (Monte et al. , 2006), which could cause a down- regulation of pro-apoptotic proteins, as disclosed in the work done by Glazer et al., 201 1 .
  • HDAC histone deacetylase 3
  • MAGE homology domain MHD
  • RING Really interesting New Gene domain proteins
  • MDM2 Interaction with Nuclear Corepressor KAP1 Contributes to p53 Inactivation (Wang et al. , 2005) and MAGE-RING Protein Complexes Comprise A Family of E3 Ubiquitin Ligases (Doyle et al.
  • MAGE-A, mMage-b, and MAGE-C Proteins Form Complexes with KAP1 and Suppress p53-dependent Apoptosis in MAGE-positive Cell Lines (Yang et al. , 2007) respectively.
  • Whether or not the evasion of apoptosis conferred by MAGE- D4b is dependent on p53 remains to be determined and it would be interesting to investigate if an interaction between MAGE-D4b and p53 exists.
  • Another hallmark of cancer is the gain in the ability of cells to metastasize, as described in The Hallmarks of Cancer (Hanahan & Weinberg, 2000) and Hallmarks of Cancer: The Next Generation (Hanahan & Weinberg, 201 1 ).
  • MAGE-D4b increased the ability of oral cancer cells to migrate but surprisingly, not invade. This is in contrast to the study published in breast cancer demonstrating that MAGE-D4b increases both migration and invasion of breast cancer cells, as described in the work done by Germano et al. , 201 1.
  • Rho family of small monomeric GTPases which is involved in promoting migration, as described in Rho GTPases and Cell Migration (Ridley AJ, 2001) and Rho GTPases: Signaling, Migration, and Invasion (Schmitz et al. , 2000).
  • Rho was up-regulated in cells exogenously expressing MAGE-D4b suggesting that MAGE-D4b could induce Rho expression to promote cell migration.
  • the ability for MAGE-D4b over-expressing cells in increasing migratory potential is in line with the association between high MAGE-D4b expressions in patients with lymph node metastasis and suggests that targeting MAGE-D4b could be effective in treating metastatic disease.
  • MAGE-D4b is up-regulated in a subset of oral squamous cell carcinoma (OSCC) and absence in normal oral mucosa tissues
  • OSCC oral squamous cell carcinoma
  • MAGE-D4b can be an ideal target for immunotherapy.
  • the direct roles of MAGE-D4b in driving oral carcinogenesis strongly suggest that it would be a good therapeutic target for oral cancer.
  • compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of the present invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the composition, methods and in the steps or in the sequence of steps of the method described herein without departing from the concept and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the scope and concept of the invention as defined by the appended claims.
  • Germano et al., MAGE-D4B is a Novel Marker of Poor Prognosis and Potential Therapeutic Target Involved in Breast Cancer Tumourigenesis, International Journal of Cancer, May 201 1 [Epub ahead of print] Glazer et al., The Role of MAGEA2 in Head and Neck Cancer, Archives of Otolaryngol - Head & Neck Surgery, Volume 137, Issue 3, pages 286-293 March 201 1 .
  • Hamid ef al. Establishment and Characterization of Asian Oral Cancer Cell Lines as in vitro Models to Study a Disease Prevalent in Asia, International Journal Molecular Medicine, Volume 19, Issue 3, pages 453-460, March 2007.
  • Neurotrophin Receptor-interacting MAGE Homologue is an Inducible Inhibitor of Apoptosis Protein-interacting Protein that Augments Cell Death, The Journal of Biological Chemistry, Volume 276, Issue 43, pages 39985-39989, September 2001 .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne un peptide comprenant au moins une séquence d'acides aminés, sélectionnée à partir d'au moins une partie de la protéine MAGE-D4b, ce peptide pouvant se lier à au moins une molécule d'antigène des leucocytes humains (HLA). La liaison du peptide à la molécule d'antigène des leucocytes humains (HLA), décrite dans cette invention, permet d'induire le système immunitaire d'un sujet de sorte que celui-ci reconnaisse des cellules buccales cancéreuses comme étrangères. Une fois reconnues comme particules étrangères, ces cellules sont ciblées et détruites par les lymphocytes T cytotoxiques CD8+. L'invention concerne en outre un vaccin contre le cancer dérivé des peptides MAGE-D4b ainsi que l'utilisation dudit vaccin contre le cancer.
PCT/MY2012/000198 2011-07-11 2012-07-05 Peptide pouvant se lier à une molécule d'antigène des leucocytes humains (hla), vaccin contre le cancer dérivé dudit peptide et utilisation dudit vaccin contre le cancer Ceased WO2013009165A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MYPI2011003259A MY170949A (en) 2011-07-11 2011-07-11 A peptide capable of binding with a human leukocyte antigen (hla) molecule, a cancer vaccine derived from said peptide and use of said cancer vaccine
MYPI2011003259 2011-07-11

Publications (1)

Publication Number Publication Date
WO2013009165A1 true WO2013009165A1 (fr) 2013-01-17

Family

ID=47506273

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MY2012/000198 Ceased WO2013009165A1 (fr) 2011-07-11 2012-07-05 Peptide pouvant se lier à une molécule d'antigène des leucocytes humains (hla), vaccin contre le cancer dérivé dudit peptide et utilisation dudit vaccin contre le cancer

Country Status (3)

Country Link
MY (1) MY170949A (fr)
TW (1) TWI567088B (fr)
WO (1) WO2013009165A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018169385A1 (fr) * 2017-03-15 2018-09-20 Cancer Research Malaysia Composition de peptide immunogène
CN110709516A (zh) * 2017-06-05 2020-01-17 国立大学法人三重大学 识别来自mage-a4的肽的抗原结合性蛋白

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114959031A (zh) * 2022-05-20 2022-08-30 上海交通大学医学院附属瑞金医院 胰腺腺癌预后评估的标志物组合及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021441A1 (en) * 2004-05-25 2010-01-28 Immatics Biotechnologies Gmbh Mhc molecule-binding tumor-associated peptides
WO2010030167A2 (fr) * 2008-09-12 2010-03-18 Cancer Research Initiative Foundation Procédé de détection et diagnostic de cancers buccaux et rhino-pharyngiens

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602005016112D1 (de) * 2005-09-05 2009-10-01 Immatics Biotechnologies Gmbh Tumorassoziierte Peptide, die HLA Klasse I oder II-Moleküle binden, und anti-Tumor Impfstoffe

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100021441A1 (en) * 2004-05-25 2010-01-28 Immatics Biotechnologies Gmbh Mhc molecule-binding tumor-associated peptides
WO2010030167A2 (fr) * 2008-09-12 2010-03-18 Cancer Research Initiative Foundation Procédé de détection et diagnostic de cancers buccaux et rhino-pharyngiens

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEONG, S. C. ET AL.: "Gene expression in human oral squamous cell carcinoma is influenced by risk factor exposure", ORAL ONCOLOGY, vol. 45, 2009, pages 712 - 719 *
CHONG, C. E. ET AL.: "Over-expression ofMAGED4B increases cell migration and growth in oral squamous cell carcinoma and is associated with poor disease outcome", CANCER LETTERS, vol. 321, no. 1, 2012, pages 18 - 26 *
KRAMER, B. F. ET AL.: "MAGED4-Expression in Renal Cell Carcinoma and Identification of an HLA-A*25-Restricted MHC Class I Ligand from Solid Tumor Tissue", CANCER BIOLOGY AND THERAPY, vol. 4, no. 9, 2005, pages 943 - 948 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018169385A1 (fr) * 2017-03-15 2018-09-20 Cancer Research Malaysia Composition de peptide immunogène
CN110494153A (zh) * 2017-03-15 2019-11-22 大马癌症研究机构 免疫原性肽组合物
JP2020515632A (ja) * 2017-03-15 2020-05-28 キャンサー リサーチ マレーシア 免疫原性ペプチド組成物
US11260118B2 (en) 2017-03-15 2022-03-01 Cancer Research Malaysia Immunogenic peptide composition
JP7103571B2 (ja) 2017-03-15 2022-07-20 キャンサー リサーチ マレーシア 免疫原性ペプチド組成物
CN110709516A (zh) * 2017-06-05 2020-01-17 国立大学法人三重大学 识别来自mage-a4的肽的抗原结合性蛋白
CN110709516B (zh) * 2017-06-05 2023-06-27 国立大学法人三重大学 识别来自mage-a4的肽的抗原结合性蛋白

Also Published As

Publication number Publication date
MY170949A (en) 2019-09-20
TW201302801A (zh) 2013-01-16
TWI567088B (zh) 2017-01-21

Similar Documents

Publication Publication Date Title
ES2378264T3 (es) Péptido antigénico de unión a HLA-DR derivado de WT1
JP6367950B2 (ja) 前立腺癌治療用組成物
UA109891C2 (uk) Композиція пухлиноасоційованих пептидів для лікування ракових захворювань
EP1923463B1 (fr) Peptide antigène dérivé du glypican-3 (gpc3) pour une utilisation chez des patients positifs à l'hla-a2 et produit pharmaceutique comprenant l'antigène
US20100168038A1 (en) Use of compounds in combination with gamma-irradiation for the treatment of cancer
JP2023071898A (ja) ＣＤ３００ｃの発現抑制剤または活性抑制剤を含む癌の予防または治療用薬学的組成物
JP2020524141A (ja) がんを処置するための方法および組成物
JP2016510596A (ja) ＰＴＤ−Ｓｍａｄ７薬物療法
WO2013009165A1 (fr) Peptide pouvant se lier à une molécule d'antigène des leucocytes humains (hla), vaccin contre le cancer dérivé dudit peptide et utilisation dudit vaccin contre le cancer
JP7181676B2 (ja) 免疫誘導剤
US20210379147A1 (en) Method and system for treating cancer utilizing tinagl1
RU2614386C2 (ru) Средство, индуцирующее иммунитет
WO2018032501A1 (fr) Nouveau polypeptide spécifique de tumeur et son application
US20180117176A1 (en) Porous silicon microparticle-based cancer vaccines and methods for potentiating anti-tumor immunity
CN113677351B (zh) 与用于癌症疗法的治疗肽相关的方法和组合物
US12144851B2 (en) Vaccinal strategy
Shi et al. Efficient growth inhibition of ErbB2-overexpressing tumor cells by anti-ErbB2 ScFv-Fc-IL-2 fusion protein in vitro and in vivo
EP1930427A1 (fr) Peptide derive d antigene de carcinome a cellules squameuses se liant a la molecule hla-a24
EP4003377A1 (fr) Cellules immunitaires à cytotoxicité améliorée et leurs procédés d'utilisation
EP3677276A1 (fr) Composition de vaccin
Gehre et al. Simon Gehre1, 2, 3, Felix Meyer4, Azzaya Sengedorj1, 2, 3, Fridolin Grottker1, 2, 3, Clara M. Reichardt1, 2, 3, Jannik Alomo1, 2, 3, Kerstin Borgmann4, Benjamin Frey1, 2, 3, Rainer Fietkau2, 3, Michael Rückert1, 2, 3 and Udo S. Gaipl1, 2, 3
WO2025034996A1 (fr) Lymphocytes t modifiés comportant des récepteurs de cellules nk et leurs utilisations
JPWO2017150595A1 (ja) 免疫誘導剤
JP2022505900A (ja) 免疫原性細胞死を誘導する合成ペプチド
HK1118079B (en) Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12811185

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12811185

Country of ref document: EP

Kind code of ref document: A1